; or (B) is vulnerable to shortage. (2) Applicable COVID–19 product definition (A) In general The term applicable COVID–19 product means a product that is included on a list that the Secretary of Health and Human Services, in consultation with the Commissioner of Food and Drugs, the Assistant Secretary for Preparedness and Response, and the Director of the Centers for Disease Control and Prevention, shall compile not later than 2 weeks after the date of enactment of this section and shall review and update, as necessary, every 2 weeks of — (i) qualified pandemic or epidemic products, as defined under section 319F–3, that are— (I) (aa) drugs, biological products, and devices that are manufactured, used, designed, developed, modified, licensed or procured— (AA) to diagnose, mitigate, prevent, treat, or cure COVID–19; or (BB) to limit the harm the COVID–19 pandemic might otherwise cause; (bb) drugs, biological products, and devices that are manufactured, used, designed, developed, modified, licensed, or procured to diagnose, mitigate, prevent, treat, or cure a serious or life-threatening disease or condition caused by a product described in item (aa); or (cc) drugs, biological products, devices or technologies intended to enhance the use or effect of a drug, biological product, or device described in item (aa) or (bb)